Kinea Bio is pioneering advancements in genetic medicine specifically targeting neuromuscular diseases through its innovative platform technologies. One of their key technologies, SIMPLI-GT™ (Split Intein Mediated Protein Ligation Gene Therapy™), addresses the limitations of adeno-associated virus (AAV) packaging by enabling the assembly of larger, functional proteins. This approach is particularly beneficial for conditions like Duchenne muscular dystrophy and dysferlinopathies, where traditional gene therapies have relied on truncated gene versions that fail to adequately alleviate symptoms. By producing full-length proteins, SIMPLI-GT™ aims to significantly improve patient outcomes and potentially halt disease progression.

In addition to SIMPLI-GT™, Kinea Bio employs MyoXpress™, a proprietary library of muscle-specific expression cassettes that optimizes the production of therapeutic proteins tailored to the varying needs of different muscle types affected by neuromuscular diseases. Their engineered myotropic capsids enhance the delivery of AAVs specifically to muscle tissues, minimizing off-target effects and reducing the required dosage, which in turn lowers safety risks and treatment costs. Furthermore, Kinea Bio's BioDrone™ technology utilizes nanovesicles derived from human cells to facilitate repeated delivery of genetic material without eliciting significant immune responses, making it suitable for conditions that require ongoing treatment, such as Myotonic Dystrophy type 1. Together, these technologies represent a comprehensive approach to addressing the unmet needs in the treatment of neuromuscular diseases.

United States

Kinea Bio is a patient-focused biotechnology company striving to accelerate the development of next-generation AAV-based gene therapies to treat various diseases. The company is located in Seattle, Washington and is dedicated to developing innovations to fight genetic diseases.

Kinea Bio

Company Details